Dr. Steven Schnittman

Dr. Schnittman is an esteemed infectious disease expert with 35 years of experience in clinical drug development and strategy. His focus is on biopharmaceutical therapeutics for virologic and immunologic diseases. He has contributed significantly to HIV/AIDS bench research, making groundbreaking immunopathogenesis discoveries. While at NIAID, NIH, he played a vital role in establishing global collaborative HIV/AIDS study groups. Throughout his 25-year biopharma career, he led the development of multiple innovative anti-HIV and anti-HCV therapies, resulting in global regulatory approvals. Currently, he consults for biopharma companies, providing expertise in clinical therapeutics development for COVID-19. He holds a B.A. and M.D. from New York University.